lapatinib has been researched along with mdv 3100 in 2 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (mdv 3100) | Trials (mdv 3100) | Recent Studies (post-2010) (mdv 3100) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 1,546 | 182 | 1,502 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Beraldi, E; Bishop, JL; Cordonnier, T; Gleave, ME; Kuruma, H; Nip, KM; Shiota, M; Takeuchi, A; Zoubeidi, A | 1 |
2 other study(ies) available for lapatinib and mdv 3100
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Nude; Neoplasm Proteins; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Y-Box-Binding Protein 1 | 2015 |